NXT LVL will be manufacturing Cannabotech’s cannabis oncology products with sales expected to begin in Q4 of 2022 in California, and later launches in the UK and Israel.
The integrative oncology products will be developed and manufactured at go NXT LVL’s facilities in accordance with the California Medical Cannabis Regulations.
Cannabotech CEO, Elhanan Shaked, stated: “This is a significant milestone in Cannabotech’s growth, allowing us entry into the world’s largest cannabis market, with unique medical solutions that will be specific and distinct from all other players in this arena.
“We are excited about finding such a professional partner as go NXT LVL, with their ability to develop and manufacture Cannabotech’s complex formulae while adhering to local medical cannabis regulations.
Read more: Cannabotech sets sights on the UK CBD market
“The vision and path we established three years ago are now becoming a reality, and we are very proud of building a solid intellectual property in Israel and starting to commercially sell our products in the world’s largest cannabis market before the end of this year.”
The company has stated that it also intends to make the scientific information it has accumulated accessible to Californian physicians and caregivers, including the research on the nine products designed to help patients with breast cancer, colon cancer, pancreatic cancer, lung cancer, prostate cancer and chemotherapy side effects such as neuropathic and inflammatory pain.
Cannabotech will be leveraging its “Forum of Experts”, including several senior Israeli oncologists, to recruit senior oncologists and therapists in California to recommend incorporating its integrative oncology products as part of the conventional anti-cancer treatment they currently prescribe.
Cannabotech will also launch its personalisation technology designed to ensure higher clinical efficiency. The technology is designed to help ensure higher clinical efficiency by allowing patients to find the most effective medical solutions for them depending on the subtype of cancer they suffer from, the anti-cancer treatment chosen by their physicians, and the patient’s genetic setup or tumour.
By partnering with NXT LVL, Cannabotech has stated it is ensuring that its products will be affordable, as NXT LVL’s location exemption from the municipal tax enables it to produce cannabis products at competitive prices.
NXT LVL has a distribution network for medical cannabis products through which it can deliver products to patient homes. Cannabotech will be utilising this distribution network as part of its California market penetration strategy.
[activecampaign form=31]
